GlassScriptPhysician profile
Shabih Hasan
NPI 1205908761
$9,009.33
in general payments reported to CMS, 2019-2025
38 companies · $2,322 in 2025
The $2,322 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,989 · 2020: $334 · 2021: $229 · 2022: $1,176 · 2023: $1,058 · 2024: $1,901 · 2025: $2,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,096 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,096.02 |
| Education | $184.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,229.52 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $723.90 | 2019-2025 | |
| Harmony Biosciences LLC | $600.71 | 2020-2025 | |
| Ucb, INC. | $597.37 | 2019-2025 | Nayzilam |
| Jazz Pharmaceuticals INC. | $558.57 | 2019-2025 | |
| Emd Serono, INC. | $547.18 | 2022-2025 | Mavenclad, Mavenclad |
| Lilly USA, LLC | $481.78 | 2019-2025 | Kisunla, Amyvid |
| Lundbeck LLC | $426.08 | 2021-2025 | Vyepti, Rexulti |
| Biogen, INC. | $405.38 | 2019-2025 | Tysabri, Vumerity, Leqembi |
| Teva Pharmaceuticals USA, INC. | $356.49 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $341.68 | 2019-2022 | |
| Tg Therapeutics, INC. | $275.05 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $244.06 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $213.00 | 2022 | |
| Inspire Medical Systems, INC. | $203.93 | 2024-2025 | Inspire |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shabih Hasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.